Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test

被引:36
|
作者
Bernal, Samuel [1 ]
Palomares, Jose C. [1 ]
Artura, Antonio [2 ]
Parra, Manuel [1 ]
Cabezas, Jose L. [1 ]
Robles, Antonio [3 ]
Martin Mazuelos, Estrella [1 ]
机构
[1] Unit Infect Dis & Clin Microbiol UCEIM HU Valme, Seville, Spain
[2] HU Valme, Dept Gynecol & Obstet, Seville, Spain
[3] HU Valme, Dept Pathol, Seville, Spain
关键词
Papillomavirus; Urine; Cobas; 4800; Genotyping; DNA DETECTION; FOLLOW-UP; CANCER; PREVENTION; EFFICACY; WOMEN;
D O I
10.1016/j.jcv.2014.10.001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Human papillomavirus (HPV) is the main cause of cervical cancer. The development of non-invasive self-sample collection methods would have the potential advantage of increasing the acceptance of the screening procedures. Objectives: To compare human papillomavirus (HPV) DNA detection and genotyping with the Cobas 4800 HPV test (Roche Diagnostic, Spain) on paired cervical and first voided urine. Study design: Paired urine and cervical samples were collected from 125 women referred for evaluation of abnormal Pap smear results. Results: The overall percent agreement between HPV detection in urine and cervical samples was 88%. A substantial concordance rate of HPV DNA detection in both samples was observed (kappa = 0.76; 95% IC: 64-87). In this high prevalence population the sensitivity, specificity, NPV and PPV for detection of HPV DNA from urine versus cervical samples were 90.5% (95% IC: 80-95%), 85%, (95% IC: 74-92%), 89.8% (95% IC: 79.5-95.3) and 86.4% (95% IC: 76.1-92.7) respectively. Compared to histologically confirmed CIN 213 disease, the clinical sensitivity and specificity for the detection of high-risk HPV in urine samples were 95% (95% IC: 76-97%) and 52.4% (95% IC: 40-64%) respectively. Conclusions: These results suggest that urine samples processed with Cobas 4800 HPV test may be useful for clinical management of HPV infection. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:548 / 552
页数:5
相关论文
共 50 条
  • [21] Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media
    Jang, Dan
    Ratnam, Sam
    Smieja, Marek
    Speicher, David J.
    Arias, Manuel
    Clavio, Avery
    Costescu, Dustin
    Elit, Laurie
    Huang, Shihai
    Herrero-Garcia, Erika
    Joseph, Ajith M.
    Jiang, Hao
    Needle, Robert
    Chernesky, Max
    TUMOUR VIRUS RESEARCH, 2021, 12
  • [22] Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing
    Demarco, Maria
    Carter-Pokras, Olivia
    Hyun, Noorie
    Castle, Philip E.
    He, Xin
    Dallal, Cher M.
    Chen, Jie
    Gage, Julia C.
    Befano, Brian
    Fetterman, Barbara
    Lorey, Thomas
    Poitras, Nancy
    Raine-Bennett, Tina R.
    Wentzensen, Nicolas
    Schiffman, Mark
    JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (05)
  • [23] Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population
    Liu, Stephanie S.
    Chan, Karen K. L.
    Wei, Tina N.
    Tse, Ka Yu
    Ngu, Siew F.
    Chu, Mandy M. Y.
    Lau, Lesley S. K.
    Cheung, Annie N. Y.
    Ngan, Hextan Y. S.
    PLOS ONE, 2022, 17 (08):
  • [24] Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment
    Stanczuk, Grazyna A.
    Currie, Heather
    Baxter, Gwen
    Foster, Adele
    Gibson, Lindsay
    Graham, Catriona
    Cuschieri, Kate
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (07) : 567 - 570
  • [25] Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
    Cook, Darrel A.
    Mei, Wendy
    Smith, Laurie W.
    van Niekerk, Dirk J.
    Ceballos, Kathy
    Franco, Eduardo L.
    Coldman, Andrew J.
    Ogilvie, Gina S.
    Krajden, Mel
    BMC CANCER, 2015, 15
  • [26] Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution
    Yang, Wan-Wei
    Wang, Zhi-Guo
    Chen, Guo-Fang
    Shi, Jian-Feng
    Chen, Juan
    Ma, Quan-Hui
    Zhou, Jing
    Mao, Xiao-Dong
    Liu, Chao
    Yao, Xiao-Ming
    CLINICAL LABORATORY, 2018, 64 (03) : 387 - 391
  • [27] Comparison of the Cobas 4800 HPV and HPV 9G DNA Chip Tests for Detection of High-Risk Human Papillomavirus in Cervical Specimens of Women with Consecutive Positive HPV Tests But Negative Pap Smears
    Jun, Sun-Young
    Park, Eun Su
    Kim, Jiyoung
    Kang, Jun
    Lee, Jae Jun
    Bae, Yoonjin
    Kim, Sang-Il
    Maeng, Lee-So
    PLOS ONE, 2015, 10 (10):
  • [28] Comparison of initial stream urine samples and cervical samples for detection of human papillomavirus
    Hagihara, Mao
    Yamagishi, Yuka
    Izumi, Koji
    Miyazaki, Narimi
    Suzuki, Takayoshi
    Kato, Hideo
    Nishiyama, Naoya
    Koizumi, Yusuke
    Suematsu, Hiroyuki
    Mikamo, Hiroshige
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (7-8) : 559 - 562
  • [29] Testing and Genotyping of High-Risk Human Papillomavirus by the cobas HPV Test and the Hybrid Capture 2 High-Risk HPV DNA Test Using Cervical and Vaginal Samples
    Pyne, Michael T.
    Law, Christian
    Hillyard, David R.
    Schlaberg, Robert
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (05) : 1720 - 1723
  • [30] The prevalence of human papillomavirus (HPV) infection in paired urine and cervical smear samples of HIV-infected women
    Jong, Eefj E.
    Mulder, Jan Willem
    van Gorp, Eric C. M.
    Wagenaar, Jiri K. S.
    Derksen, Joke
    Westerga, Johan
    Tol, Anja
    Smits, Paul H. M.
    JOURNAL OF CLINICAL VIROLOGY, 2008, 41 (02) : 111 - 115